Allena Pharmaceuticals to Present at 40th Annual Cowen & Co. Health Care Conference

NEWTON, Mass., Feb. 24, 2020 — Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will present a corporate overview at the 40th Annual Cowen & Co. Health Care Conference on Monday, March 2, 2020 at 4:10 p.m. ET in Boston, MA.

A live audio webcast of the presentation will be available under “Events and Presentations” in the Investors section of the Company’s website at www.allenapharma.com. A replay of the webcast will be available on the Allena website for 30 days following the presentation.

About Allena Pharmaceuticals Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

Investor Contact Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200 [email protected]

Media Contact Adam Daley Berry & Company Public Relations 212-253-8881 [email protected]

Allena Pharmaceuticals to Present at 40th Annual Cowen & Co. Health Care Conference 1

Primary Logo